- Trials with a EudraCT protocol (61)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
61 result(s) found for: Washing.
Displaying page 3 of 4.
EudraCT Number: 2012-005409-38 | Sponsor Protocol Number: TriSulfa-FPI-1 | Start Date*: 2013-04-19 | |||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) | |||||||||||||
Full Title: Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis | |||||||||||||
Medical condition: Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002201-25 | Sponsor Protocol Number: CHDR2007 | Start Date*: 2020-12-14 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: A two-part (observational and intervention) study to explore disease characteristics of vulvar (pre)malignancies compared to healthy volunteers | ||
Medical condition: lichen sclerosus, vulvar (pre)malignancies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003304-39 | Sponsor Protocol Number: 007 | Start Date*: 2019-01-23 | ||||||||||||||||
Sponsor Name:Morten Rasmussen | ||||||||||||||||||
Full Title: Efficacy of a novel 1l PEG plus ascorbate (Plenvu) bowel preparation vs. 2l PEG plus ascorbate (Moviprep), a randomized controlled multicenter trial | ||||||||||||||||||
Medical condition: Bowel preparation before colonoscopy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001051-12 | Sponsor Protocol Number: 1708213 | Start Date*: 2018-09-07 | ||||||||||||||||
Sponsor Name:CHU Saint-Etienne | ||||||||||||||||||
Full Title: VEDO - PREDIRESPUC project - Value of pharmacokinetic assays (Vedolizumab and anti-vedolizumab antibody) in the prediction of induction and maintenance therapeutic response in Ulcerative Colitis | ||||||||||||||||||
Medical condition: Ulcerative Colitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000762-18 | Sponsor Protocol Number: CRN00808-11 | Start Date*: 2023-01-24 | |||||||||||
Sponsor Name:Crinetics Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome. | |||||||||||||
Medical condition: Carcinoid Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002872-15 | Sponsor Protocol Number: 1203/12 | Start Date*: 2012-09-13 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Hyperthermic intra-peritoneal chemotherapy (HIPEC) in Ovarian cancer recurrence: Randomized trial on Survival Evaluation. | |||||||||||||
Medical condition: Ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000732-29 | Sponsor Protocol Number: CA184-124 | Start Date*: 2012-04-30 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab versus Pemetrexed in Subjects with Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed Afte... | ||
Medical condition: NSCLC is the description of a malign development of body tissues from cells in the Bronchia / Lungs where larger cells are visible per microscope. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-003534-25 | Sponsor Protocol Number: CS8635-A-E302 | Start Date*: 2009-05-13 | |||||||||||
Sponsor Name:DAIICHI SANKYO EUROPE GmbH | |||||||||||||
Full Title: A randomised, double-blind, parallel group study evaluating the efficacy and safety of co administration of triple combinations of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide... | |||||||||||||
Medical condition: Essential hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) DE (Completed) NL (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) BG (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004309-15 | Sponsor Protocol Number: MK-3475-604 | Start Date*: 2017-05-10 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of... | |||||||||||||
Medical condition: First-line treatment of extensive stage small cell lung cancer (ES-SCLC) in combination with standard of care (SOC) chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) FR (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023963-16 | Sponsor Protocol Number: 1014802/202 | Start Date*: 2012-01-05 | |||||||||||
Sponsor Name:Convergence Pharmaceuticals Ltd | |||||||||||||
Full Title: A Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuragia | |||||||||||||
Medical condition: Trigeminal neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) DK (Completed) IT (Completed) ES (Completed) LV (Completed) LT (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023310-31 | Sponsor Protocol Number: MagicBullet/COLMER | Start Date*: 2011-02-07 | |||||||||||
Sponsor Name:Consorcio de apoyo a la Investigación Biomédica en Red (CAIBER) | |||||||||||||
Full Title: Ensayo clínico en fase IV aleatorizado, abierto, multicéntrico y de no inferioridad para comparar la seguridad y la eficacia de colistina iv. con meropenem iv. en el tratamiento de la neumonía asoc... | |||||||||||||
Medical condition: Neumonía asociada a ventilación mecánica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005905-79 | Sponsor Protocol Number: OSI-774-203 | Start Date*: 2007-03-13 | |||||||||||
Sponsor Name:OSI Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumo... | |||||||||||||
Medical condition: Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001923-53 | Sponsor Protocol Number: 7980 | Start Date*: 2015-10-07 | |||||||||||
Sponsor Name:Rafael Bielza Galindo | |||||||||||||
Full Title: Intravenous iron, early functional recovery and delirium in patients atients with hip fracture | |||||||||||||
Medical condition: Hip fracture | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000852-40 | Sponsor Protocol Number: TBSH-01 | Start Date*: 2012-08-03 | ||||||||||||||||
Sponsor Name:Dermal Laboratories | ||||||||||||||||||
Full Title: A double-blind, placebo-controlled study determining the efficacy of terbinafine shampoo in the treatment of pityriasis capitis and seborrhoeic dermatitis. | ||||||||||||||||||
Medical condition: The two severe dandruff conditions to be investigated in this study are pityriasis capitis and seborrhoeic dermatitis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005230-15 | Sponsor Protocol Number: GECP20/06 | Start Date*: 2022-08-04 | |||||||||||
Sponsor Name:Fundación GECP | |||||||||||||
Full Title: A Phase II study of pembrolizumab, lenvatinib and chemotherapy combination in first line extensive-stage small cell lung cancer (ES-SCLC) | |||||||||||||
Medical condition: First line treatment for extensive-stage small cell lung cancer small cell lung cancer patients (ES-SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000471-20 | Sponsor Protocol Number: RIPH_2019_01 | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:CH Tourcoing | |||||||||||||
Full Title: Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-la... | |||||||||||||
Medical condition: Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001111-31 | Sponsor Protocol Number: 20101128 | Start Date*: 2013-09-09 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer | |||||||||||||
Medical condition: Metastatic Non-Squamous Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004843-22 | Sponsor Protocol Number: MK-7339-005 | Start Date*: 2020-02-04 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Phase 3 Study of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Part... | |||||||||||||
Medical condition: Extensive Stage Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) PL (Completed) ES (Prematurely Ended) FR (Prematurely Ended) BE (Completed) HU (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002604-25 | Sponsor Protocol Number: CA184-153 | Start Date*: 2014-10-22 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subj... | |||||||||||||||||||||||
Medical condition: LUNG CANCER (NSCLC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) DE (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007669-20 | Sponsor Protocol Number: 37822681SCH2003 | Start Date*: 2008-08-18 |
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | ||
Full Title: A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stabl... | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) SE (Prematurely Ended) BE (Completed) SK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
